Substantial controversy arose in 2021 when the Food and Drug Administration (FDA) approved the Alzheimer’s disease drug aducanumab (Aduhelm) under its accelerated approval program despite a nearly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results